Gossamer Bio, Inc. (NASDAQ: GOSS) is a Healthcare company (Biotechnology) with a market capitalization of $68M. The Maz Rating grades it against the other companies in its sector.
Gossamer Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $11.04, Gossamer Bio, Inc. trades at 0.8x sales. Over the last twelve months it generated about $83M of revenue and a net loss of $232M. It runs a gross margin of 99.7%, an operating margin of -140.0% and a net margin of -159.5%. It shows return on equity of 99.8%, return on invested capital of -4305.6% and a free cash flow yield of -230.8%. On the balance sheet: a debt-to-equity ratio of -0.33 and a current ratio of 0.60. Over the past 52 weeks the share price ranged from $8.29 to $309.60, with a beta of 2.00.
Gossamer Bio, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 11 Buy, 5 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Gossamer Bio, Inc. (GOSS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 103.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 143.0% / 30% · Interest income / Revenue 1.04% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 103.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 143.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1.04% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 103.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 143.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1.04% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 106.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 77.8% / 33.33% · Receivables / Avg Assets (4Q) 6.33% / 33.33% · Interest income / Revenue 1.04% / 5% | Fail |
| FTSE | Debt / Total Assets 57.7% / 33.33% · (Cash+ST Inv) / Total Assets 79.6% / 33.33% · (Cash+Recv) / Total Assets 79.6% / 33.33% · Interest income / Revenue 1.04% / 5% | Fail |
No. As of September 2026, Gossamer Bio, Inc. (GOSS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Gossamer Bio, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 1.04% of each dividend: Gossamer Bio, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.